GSK2982772 Modified Release
Sponsors
GlaxoSmithKline
Conditions
Autoimmune Diseases
Phase 1
A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses
CompletedNCT03266172
Start: 2017-09-27End: 2018-11-21Updated: 2021-08-13
A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772
CompletedNCT03649412
Start: 2018-09-26End: 2019-05-07Updated: 2020-05-01